PT Kalbe Farma Tbk stock (ID1000096605): valuation focus as Jakarta shares ease

PT Kalbe Farma Tbk shares on the Indonesia Stock Exchange traded moderately lower on 06/05/2026, drawing investor attention to current valuation metrics and recent earnings for the Jakarta-based pharmaceutical group.

PT Kalbe Farma Tbk shares, listed on the Indonesia Stock Exchange in Jakarta under the ticker KLBF, changed hands around 710 IDR on 06/05/2026, down about 1.4% on the day according to TradingView data sourced from IDX as of 06/05/2026, highlighting a modest pullback in one of Indonesia's largest pharmaceutical names.TradingView as of 06/05/2026

The movement in PT Kalbe Farma Tbk comes against a broader backdrop of volatility in Indonesian equities, with investors tracking earnings, currency trends and sector-specific developments as they reassess valuations in the local health-care and consumer segments.

As of: 06/05/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Kalbe Farma
• Sector/industry: Pharmaceuticals and consumer health
• Headquarters/country: Jakarta, Indonesia
• Core markets: Indonesia and selected Southeast Asian countries
• Key revenue drivers: Prescription drugs, over-the-counter medicines, nutritionals, and distribution services
• Home exchange/listing venue: Indonesia Stock Exchange (KLBF)
• Trading currency: IDR

PT Kalbe Farma Tbk: core business model

PT Kalbe Farma Tbk operates as a diversified healthcare group in Indonesia, generating revenue primarily from branded pharmaceuticals, consumer health products, nutritional items, and an extensive domestic distribution network that supplies pharmacies, hospitals, and retail channels.

Valuation metrics and multiples for PT Kalbe Farma Tbk

Investors focusing on valuation for PT Kalbe Farma Tbk on 06/05/2026 are looking at the current share price near 710 IDR on the Indonesia Stock Exchange, which serves as the key input for equity multiples such as price-to-earnings and enterprise-value-based ratios, even though the most up-to-date full-year earnings release and detailed multiple breakdowns are not cited here from a primary company filing.Kalbe Farma investor relations as of 06/05/2026

While precise current-year valuation metrics require reference to the latest audited financials and market capitalization data from official sources in Jakarta, the stock's moderate intraday decline around 1.4% on 06/05/2026 at approximately 710 IDR, based on Indonesia Stock Exchange pricing disseminated via TradingView, underscores how even small price moves can shift headline valuation ratios in a relatively defensive sector such as pharmaceuticals.TradingView as of 06/05/2026

Conclusion

PT Kalbe Farma Tbk's share price near 710 IDR on 06/05/2026 on the Indonesia Stock Exchange, reflecting a roughly 1.4% intraday decline, places the Jakarta-based pharmaceutical group under closer scrutiny from investors comparing its valuation with regional peers and local market conditions. With the current level serving as a reference point for key multiples such as price-to-earnings and enterprise-value measures, participants will look to upcoming financial disclosures and sector developments to refine their view of whether the present pricing adequately captures Kalbe Farma's earnings profile and growth prospects in Indonesia's healthcare market.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.